<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02152956</url>
  </required_header>
  <id_info>
    <org_study_id>CP-MGD006-01</org_study_id>
    <nct_id>NCT02152956</nct_id>
  </id_info>
  <brief_title>Safety Study of MGD006 in Relapsed/Refractory Acute Myeloid Leukemia (AML) or Intermediate-2/High Risk MDS</brief_title>
  <official_title>A Phase 1, First in Human, Dose Escalation Study of MGD006, a CD123 x CD3 Dual Affinity Re-Targeting (DART®) Bi-Specific Antibody Based Molecule, in Patients With Relapsed or Refractory AML or Intermediate-2/High Risk MDS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MacroGenics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut de Recherches Internationales Servier</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>MacroGenics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of this Phase 1, dose-escalation study, is to determine the maximum
      tolerated dose level of MGD006 in patients with AML and MDS whose disease is not expected to
      benefit from cytotoxic chemotherapy. Studies will also be done to see how the drug acts in
      the body (pharmacokinetics [PK], pharmacodynamics) and to evaluate potential anti-tumor
      activity of MGD006.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open-label, multi-dose, single-arm, multi-center, Phase 1, dose-escalation study to define a
      maximum tolerated dose and schedule (MTDS), describe preliminarily safety, and to assess PK,
      immunogenicity, immunomodulatory activity, and potential anti-tumor activity of MGD006 in
      patients with AML or MDS whose disease is not expected to benefit from cytotoxic
      chemotherapy.

      This study is designed in three segments: the Single Patient Dose Escalation Segment,
      followed by the Multi-Patient Dose Escalation Segment and the MTDS Expansion Cohort Segment.

      The Multi-Patient Dose Escalation Segment will employ a classical 3+3 scheme to examine a
      series of increasing dose escalations in cohorts of patients with either AML or MDS. Patients
      will be enrolled in one of the two available dosing schedules.

      Once the MTDS is established, the cohort of patients treated at that dose/schedule or a lower
      dose, will be expanded with the addition of 2 cohorts of 24 patients each (1 cohort for AML
      and 1 cohort for MDS) to increase the safety experience and more fully evaluate the PK,
      pharmacodynamics, and activity of MGD006.

      In all segments of the study, patients who benefit from MGD006 treatment, and continue to
      meet eligibility, may continue treatment in Cycles 2 and beyond.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of dose limiting toxicity</measure>
    <time_frame>Cycle 1 of a 28 day cycle.</time_frame>
    <description>• Maximum Tolerated Dose/Schedule: the MTDS will be defined as the highest dose/schedule administered during any Cohort in the study at which the incidence of DLT is &lt; 33% during the first cycle of MGD006 treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>Cycle 1 through end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of anti-drug antibody (ADA)</measure>
    <time_frame>Cycle 1 through end of treatment (28 day cycles)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of anti-leukemic activity</measure>
    <time_frame>Every 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure the pharmacokinetics (PK) of MGD006</measure>
    <time_frame>Cycle 1 through end of treatment (28 day cycles)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>AML</condition>
  <condition>MDS</condition>
  <arm_group>
    <arm_group_label>MGD006</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MGD006, a CD123 x CD3 Dual Affinity Re-Targeting (DART®) bi-specific antibody</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MGD006</intervention_name>
    <description>MGD006 is a CD123 x CD3 bi-specific antibody-based molecular construct referred to as a Dual Affinity Re-Targeting (DART®) molecule. MGD006 will be administered as a single agent.</description>
    <arm_group_label>MGD006</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of primary or secondary AML [any subtype except acute
             promyelocytic leukemia (APL)] according to World Health Organization (WHO)
             classification or MDS with an International Prognostic Scoring System (IPSS) risk
             category of Intermediate 2 or High Risk

          -  Patients with AML must be unlikely to benefit from cytotoxic chemotherapy defined by
             any one of the following criteria:

               -  leukemia refractory to ≥ 2 induction attempts,

               -  leukemia in 1st relapse with initial CR duration &lt; 6 months,

               -  leukemia in 1st relapse following ≥ 1 unsuccessful salvage attempts,

               -  leukemia in 2nd or higher relapse,

               -  prior treatment failure with at least two cycles of hypomethylating agent.

          -  Patients with MDS must have experienced treatment failure with at least one cycle of
             hypomethylating therapy or induction therapy and have ≥ 10% bone marrow blasts

          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤2

          -  Life expectancy of at least 4 weeks

          -  Peripheral blast count &lt;/= 20,000/mm3 at the time of initiation of infusion on Cycle 1
             Day 1

          -  Acceptable laboratory parameters and adequate organ reserve

          -  Adult (≥ 18 years old)

        Exclusion Criteria:

          -  Prior history of allogeneic stem cell transplantation

          -  Prior treatment with an anti-CD123-directed agent

          -  Need for concurrent other cytoreductive chemotherapy

          -  Any prior history of or suspected current autoimmune disorders (with the exception of
             vitiligo, resolved childhood atopic dermatitis, prior Grave's disease now euthyroid
             clinically and by laboratory testing)

          -  Second primary malignancy that requires active therapy. Adjuvant hormonal therapy is
             allowed.

          -  Previous treatment with radiotherapy or immunotherapeutic agents in the 4 weeks prior
             to study drug administration (Cycle 1 Day 1)

          -  Previous treatment with any other investigational agent in the 4 weeks prior to study
             drug administration (Cycle 1 Day 1)

          -  Requirement, at the time of study entry, for concurrent steroids &gt; 10 mg/day of oral
             prednisone or the equivalent, except steroid inhaler, nasal spray or ophthalmic
             solution

          -  Use of immunosuppressant medications in the 2 weeks prior to study drug administration
             (Cycle 1 Day 1)

          -  Use of granulocyte colony stimulating or granulocyte-macrophage colony stimulating
             factor in the 2 weeks prior to study drug administration (Cycle 1 Day 1)

          -  Known central nervous system (CNS) leukemia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John DiPersio, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jan Davidson-Moncada, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>MacroGenics</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Norbert Vey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute Paoli-Calmettes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kathy Tran</last_name>
    <email>trank@Macrogenics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Nimm</last_name>
      <phone>404-778-4994</phone>
      <email>joseph.nimm@emory.edu</email>
    </contact>
    <investigator>
      <last_name>H. Jean Khoury, MD, FACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ayan Gasanli</last_name>
      <phone>314-747-2449</phone>
      <email>agasanli@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Geoffrey Uy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>John DiPersio, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina Lineberger Comprehensive Cancer Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jack Zhang</last_name>
      <phone>984-974-8251</phone>
      <email>jack_zhang@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Mathew C. Foster, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Stowe, BSN, RN</last_name>
      <phone>919-681-4769</phone>
      <email>rachel.stowe@duke.edu</email>
    </contact>
    <investigator>
      <last_name>David Rizzieri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neysa Dagostino, RN, OCN</last_name>
      <phone>503-215-2608</phone>
      <email>neysa.dagostino@providence.org</email>
    </contact>
    <investigator>
      <last_name>John Godwin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Paoli-Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13002</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Veuillen</last_name>
      <email>veuillenc@ipc.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Norbert Vey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik und II, Universitätsklinikum Würzburg</name>
      <address>
        <city>Würzbur</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johana Reif</last_name>
      <email>Reif_J@ukw.de</email>
    </contact>
    <investigator>
      <last_name>Max Topp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico Sant'Orsola Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Federica Frabetti</last_name>
      <email>federica.frabetti2@studio.unibo.it</email>
    </contact>
    <investigator>
      <last_name>Giovanni Martinelli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Vita-Salute San Raffaele</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefania Trinca</last_name>
      <email>trinca.stefania@hsr.it</email>
    </contact>
    <investigator>
      <last_name>Fabio Ciceri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9713</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erna Helmantel</last_name>
      <email>e.helmantel@umcg.nl</email>
    </contact>
    <investigator>
      <last_name>Gerwin Huls, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus University Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3075</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Longergan</last_name>
      <email>s.lonergan@erasmusmc.nl</email>
    </contact>
    <investigator>
      <last_name>Bob Lowenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 28, 2014</study_first_submitted>
  <study_first_submitted_qc>May 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2014</study_first_posted>
  <last_update_submitted>September 12, 2017</last_update_submitted>
  <last_update_submitted_qc>September 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>leukemia</keyword>
  <keyword>myelogenous</keyword>
  <keyword>myeloid</keyword>
  <keyword>refractory</keyword>
  <keyword>MDS</keyword>
  <keyword>Myelodysplastic</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Bispecific</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

